ARS Pharmaceuticals Hits New 52-Week Low at $8.90 Amid Financial Struggles

ARS Pharmaceuticals, Inc., a small-cap player in the Pharmaceuticals & Biotechnology sector, has reached a new 52-week low of USD 8.90 on October 29, 2025. This decline marks a significant downturn for the company, which has seen its stock price drop by 37.36% over the past year, contrasting sharply with the S&P 500's performance of 18.33% during the same period.
The company's financial metrics reveal a challenging landscape. With a market capitalization of USD 1,057 million, ARS Pharmaceuticals is currently operating at a loss, reflected in its negative price-to-earnings ratio and a return on equity of -24.97%. The firm has also reported a substantial increase in raw material costs, up 29.47% year-over-year, contributing to an operating profit of USD -47.33 million.

Despite a brief period of positive results earlier in 2025, the company has faced setbacks, including a negative EBITDA and a return on capital employed (ROCE) of -23.56%. The stock's performance indicates a struggle to maintain momentum in a competitive market, as it continues to underperform relative to broader market indices.